Attached files
| file | filename |
|---|---|
| EX-32.1 - EX-32.1 - Corvus Pharmaceuticals, Inc. | crvs-20191231ex3210c2734.htm |
| EX-31.2 - EX-31.2 - Corvus Pharmaceuticals, Inc. | crvs-20191231ex312bc6e82.htm |
| EX-31.1 - EX-31.1 - Corvus Pharmaceuticals, Inc. | crvs-20191231ex311da44ef.htm |
| EX-10.18 - EX-10.18 - Corvus Pharmaceuticals, Inc. | crvs-20191231ex1018cd3ce.htm |
| EX-10.17(B) - EX-10.17(B) - Corvus Pharmaceuticals, Inc. | crvs-20191231ex1017b16cd.htm |
| EX-10.16(C) - EX-10.16(C) - Corvus Pharmaceuticals, Inc. | crvs-20191231ex1016cdf22.htm |
| EX-10.16(B) - EX-10.16(B) - Corvus Pharmaceuticals, Inc. | crvs-20191231ex1016b82ec.htm |
| EX-4.5 - EX-4.5 - Corvus Pharmaceuticals, Inc. | crvs-20191231ex45adb3c49.htm |
| 10-K - 10-K - Corvus Pharmaceuticals, Inc. | crvs-20191231x10k.htm |
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We hereby consent to the incorporation by reference in the Registration Statements on Form S-3 (No. 333-217102), and Form S-8 (No. 333-223622, No. 333-216590, No. 333-210456 and No. 333-231331) of Corvus Pharmaceuticals. Inc. of our report dated March 9, 2020 relating to the financial statements, which appears in this Form 10-K.
/s/ PricewaterhouseCoopers LLP
San Jose, California
March 9, 2020